Vela, Protagen sign agreement
Austria-based Vela offers research activities to clinical phases and up to product commercialization to its customers. VELA CEO Markus Fido said their customers will benefit from this alliance
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.